Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 17/20 | 1.00 |
| ▸ | MAOA | P21397 | 14/20 | 0.84 |
| ▸ | MAOB | P27338 | 12/20 | 0.84 |
| ▸ | RCOR1 | Q9UKL0 | 7/20 | 0.84 |
| ▸ | KDM1B | Q8NB78 | 4/20 | 0.84 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17287978 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| Hydrochloric Acid SCHEMBL15789049 | 0.99 | KDM1A (0.97) | KDM1AMAOAMAOBRCOR1KDM1B | |
| Hydrochloric Acid SCHEMBL15789047 | 0.99 | KDM1A (0.97) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL17003580 | 0.91 | MAOA (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL15944933 | 0.91 | KDM1A (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL21471753 | 0.91 | KDM1A (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL12813993 | 0.91 | KDM1A (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL2557921 | 0.91 | KDM1A (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL17003579 | 0.91 | MAOA (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| Hydrochloric Acid SCHEMBL15789125 | 0.90 | KDM1A (1.00) | KDM1AMAOAMAOBRCOR1KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3224352-B1 | REPROGRAMMING-BASED MODELS OF NEURODEVELOPMENTAL DISORDERS AND USES THEREOF | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2024-01-03 | — | — | EP | claimed |
| EP-2560949-B1 | TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASE LSD1 AND/OR LSD2 | UNIVERSIT DEGLI STUDI DI ROMA LA SAPIENZA (IT) | 2015-12-02 | — | — | EP | claimed |
| US-8765820-B2 | Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2 | Universita Degli Studi Di Roma “La Sapienza” (IT) | 2014-07-01 | — | — | US | claimed |
| EP-2560949-A1 | TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASE LSD1 AND/OR LSD2 | Università degli Studi di Roma "La Sapienza" (IT) | 2013-02-27 | — | — | EP | claimed |
| US-20130035377-A1 | TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASES LSD1 AND/OR LSD2 | UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) | 2013-02-07 | — | — | US | claimed |
| WO-2011131576-A1 | TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASE LSD1 AND/OR LSD2 | UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) | 2011-10-27 | — | — | WO | claimed |
| US-11918580-B2 | Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20210100800-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | INSTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2021-04-08 | — | — | US | disclosed |
| US-10233165-B2 | Cyclopropylamine compounds as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2019-03-19 | — | — | US | disclosed |
| US-20180311245-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH CDK2 INHIBITORS IN THE TREATMENT OF CANCER | RASNA THERAPEUTICS LTD (GB) | 2018-11-01 | — | — | US | disclosed |
| WO-2018197583-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | ISTITUTO EUROPEO DI ONCOLOGIA (IT) | 2018-11-01 | — | — | WO | disclosed |
| EP-3148974-B1 | CYCLOPROPYLAMINE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2018-09-26 | — | — | EP | disclosed |
| WO-2017097865-A9 | COMBINATION OF CALORIC RESTRICTION (CR) OR IGF1/INSULIN RECEPTOR INHIBITOR WITH LSD1 INHIBITOR | ISTITUTO EUROPEO DI ONCOLOGIA (IT) | 2017-08-31 | — | — | WO | disclosed |
| US-20170190680-A1 | CYCLOPROPYLAMINE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2017-07-06 | — | — | US | disclosed |
| WO-2017097865-A1 | COMBINATION OF CALORIC RESTRICTION (CR) OR IGF1/INSULIN RECEPTOR INHIBITOR WITH LSD1 INHIBITOR | ISTITUTO EUROPEO DI ONCOLOGIA (IT) | 2017-06-15 | — | — | WO | disclosed |
| CN-103842332-B | Cyclopropylamine compound | 武田药品工业株式会社 | 2016-08-17 | — | — | CN | disclosed |
| EP-2560949-B1 | TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASE LSD1 AND/OR LSD2 | UNIVERSIT DEGLI STUDI DI ROMA LA SAPIENZA (IT) | 2015-12-02 | — | — | EP | disclosed |
| US-8765820-B2 | Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2 | Universita Degli Studi Di Roma “La Sapienza” (IT) | 2014-07-01 | — | — | US | disclosed |
| US-20130035377-A1 | TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASES LSD1 AND/OR LSD2 | UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311245-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH CDK2 INHIBITORS IN THE TREATMENT OF CANCER | CDK2, EZH2, CDK6 | KDM1A 16/4885MAOA 1955/4885MAOB 1751/4885 |
| US-20210100800-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | CDK6, KDM1B, KDM6B | KDM1A 7/4885MAOA 1440/4885MAOB 1514/4885 |
| US-20130035377-A1 | TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASES LSD1 AND/OR LSD2 | KDM1B, KDM2A, KDM3A | KDM1A 4/4885MAOA 103/4885MAOB 72/4885 |
| US-11918580-B2 | Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | CDK6, KDM1B, KDM6B | KDM1A 7/4885MAOA 1440/4885MAOB 1514/4885 |
| US-10233165-B2 | Cyclopropylamine compounds as histone demethylase inhibitors | KDM1B, PHF2, KDM6B | KDM1A 12/4885MAOA 439/4885MAOB 425/4885 |
| US-20170190680-A1 | CYCLOPROPYLAMINE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | KDM1B, PHF2, KDM6B | KDM1A 12/4885MAOA 439/4885MAOB 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.